Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma

Background: The approval of immune checkpoint inhibitors in combination with specific diagnostic biomarkers presents new challenges to pathologists as tumor tissue needs to be tested for expression of programmed death-ligand 1 (PD-L1) for a variety of indications. As there is currently no requiremen...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribbat-Idel, Julika, Dressler, Franz F., Krupar, Rosemarie, Watermann, Christian, Paulsen, Finn-Ole, Kuppler, Patrick, Klapper, Luise, Offermann, Anne, Wollenberg, Barbara, Rades, Dirk, Laban, Simon, Reischl, Markus, Bruchhage, Karl-Ludwig, Idel, Christian, Perner, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110724/
https://www.ncbi.nlm.nih.gov/pubmed/33987192
http://dx.doi.org/10.3389/fmed.2021.640515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110724/
https://www.ncbi.nlm.nih.gov/pubmed/33987192
http://dx.doi.org/10.3389/fmed.2021.640515

Ejemplares similares